Yoshito Takeda

Crest
Suita, 5650871, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 165 publications

Mycobacterium brisbanense Pulmonary Disease Treated with a Macrolide-Based Multidrug Regimen: A Case Report.

Mycobacterium brisbanense Pulmonary Disease Treated with a Macrolide-Based Multidrug Regimen: A Case Report.

Journal: Internal medicine (Tokyo, Japan)

Published: June 10, 2026

Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer.

Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 08, 2026

Clinical implications of serum GDF15 propeptide as a biomarker for bone metastasis across common solid tumors: a real-world multi-institutional study.

Clinical implications of serum GDF15 propeptide as a biomarker for bone metastasis across common solid tumors: a real-world multi-institutional study.

Journal: Biomarker research

Published: April 29, 2026

Comparison of Long-Term Survival Between Nivolumab Plus Ipilimumab and Nivolumab Plus Ipilimumab With Chemotherapy in Advanced NSCLC: A Multicenter Retrospective Cohort Study.

Comparison of Long-Term Survival Between Nivolumab Plus Ipilimumab and Nivolumab Plus Ipilimumab With Chemotherapy in Advanced NSCLC: A Multicenter Retrospective Cohort Study.

Journal: JTO clinical and research reports

Published: March 24, 2026

Late-Onset Acute Cellular Rejection after Lung Transplantation Triggered by a Fluctuation in the Tacrolimus Trough Level Which Was Successfully Treated with Steroid Pulse Therapy.

Late-Onset Acute Cellular Rejection after Lung Transplantation Triggered by a Fluctuation in the Tacrolimus Trough Level Which Was Successfully Treated with Steroid Pulse Therapy.

Journal: Internal medicine (Tokyo, Japan)

Published: March 18, 2026

Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicenter Retrospective Study.

Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicenter Retrospective Study.

Journal: Thoracic cancer

Published: January 31, 2026

Reply.

Reply.

Journal: The journal of allergy and clinical immunology. Global

Published: January 09, 2026

Impact of pre-existing interstitial lung abnormalities on pneumonitis risk and survival in chemo-naive patients with non-small-cell lung cancer receiving pembrolizumab plus chemotherapy.

Impact of pre-existing interstitial lung abnormalities on pneumonitis risk and survival in chemo-naive patients with non-small-cell lung cancer receiving pembrolizumab plus chemotherapy.

Journal: Respiratory medicine

Published: December 24, 2025

Identification of predictive biomarkers for nivolumab efficacy in non-small cell lung cancer through integrated serum lipidomics and proteomics analysis.

Identification of predictive biomarkers for nivolumab efficacy in non-small cell lung cancer through integrated serum lipidomics and proteomics analysis.

Journal: Frontiers in immunology

Published: December 23, 2025

Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study.

Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 03, 2025

Subset binding enables detection of multimodal patient subgroup patterns and drug target discovery in idiopathic pulmonary fibrosis.

Subset binding enables detection of multimodal patient subgroup patterns and drug target discovery in idiopathic pulmonary fibrosis.

Journal: Briefings in bioinformatics

Published: November 23, 2025

Impact of Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors on Anti-PD-1 Antibody-Bound T-Cell Dynamics and Clinical Outcomes.

Impact of Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors on Anti-PD-1 Antibody-Bound T-Cell Dynamics and Clinical Outcomes.

Journal: Cancer science

Published: November 17, 2025

Showing 1-12 of 165

Last Updated: 09/26/2026